Deciphering the pharmacological mechanisms of salidroside in cervical cancer by combining network pharmacology, molecular docking, and in vitro studies Authors: Jianmin Wang, Guanghui Song, Liaqat Hussain, Lili Xing Published: 2025 ABSTRACT Cervical cancer is one of the major and serious risks to women. Salidroside, a natural compound, shows promise in treating cervical cancer. However, its specific molecular mechanisms remain unclear and require further investigation. This study aimed to elucidate the pharmacological activity of salidroside and its underlying molecular mechanisms in cervical cancer, employing network pharmacology, molecular docking, and experimental approaches. Genes associated with cervical cancer were gathered from The Cancer Genome Atlas Program (TCGA), Gene Expression Omnibus (GEO) databases, and network pharmacology. Furthermore, we integrated the drug targets with the disease targets pertinent to cervical cancer, subsequently conducting analyses utilizing the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) to explain the pharmacological pathways through which salidroside operates in the milieu of cervical cancer. Survival analysis was performed to screen the core therapeutic targets of salidroside. Salidroside constituents and hub genes binding affinity were assessed by molecular docking studies. In vitro experiments, including Cell Counting Kit-8 (CCK-8) assays, flow cytometry, and western blotting, were performed to further validate the computational findings. Study findings revealed that salidroside inhibited the cervical cancer cell progression, reduced viability, and induced apoptosis.Ten target genes related to salidroside’s anti-cancer effects have been identified. Survival analysis revealed that MMP1 and MMP3 exhibited the highest binding capability among all the target genes. Molecular docking indicated that the salidroside’s active entities showed a strong binding tendency with the MMP1 and MMP3 genes. Western blot analysis revealed that it significantly reduced the expression of MMP-1 and MMP-3. In Vitro studies suggested that suppressing MMP1 and MMP3 genes might be responsible for salidroside’s anticancer effects.Supplementary InformationThe online version contains supplementary material available at 10.1007/s44446-025-00052-0. Introduction Cervical cancer is reported as a critical gynecological cancer, particularly affecting women in low- and middle-income nations. It is the fourth most prevalent cancer, which affects women worldwide, with approximately 342,000 deaths and 604,000 new cases in 2020 (Basen-Engquist et al. 2003; Buskwofie et al. 2020; Bray et al. 2024; Duska et al. 2024). Even with improvements in screening and prevention, cervical cancer is still a morbid disorder, especially in areas with restricted healthcare facilities. The 5-year survival rate varies widely, ranging from over 90% for early-stage diagnoses to less than 20% for advanced or metastatic disease (Moore 2006; Sankaranarayanan et al. 2008; Arbyn et al. 2020). Early detection through routine Pap smears and HPV testing has reduced cervical cancer occurrence and mortality in developed nations, but these screening programs are often inaccessible in resource-limited settings (Gakidou et al. 2008). Cervical cancer treatment strategies are dependent on its staging. Early-stage disease is often treated with surgery or radiotherapy, which can be curative (Bhatla et al. 2018). However, for advanced or recurrent disease, treatment options are limited and primarily involve platinum-based chemotherapy combined with radiotherapy, which often results in significant toxicities and modest survival benefits (From the Meta-Analysis Group 2008, Tewari et al. 2014). Targeted therapies, such as bevacizumab, and immunotherapy, including immune checkpoint inhibitors, have shown promise in recent years, but their efficacy remains limited, and they are not widely accessible (Frenel et al. 2017; Marth et al. 2017). Therefore, developing new therapeutic drugs remains essential. Salidroside, a naturally occurring phenolic compound obtained from Rhodiola rosea, has recently emerged as a promising anti-tumor agent due to its multifaceted mechanisms of action. Studies have demonstrated that salidroside inhibited cancer cell spread, induced apoptosis, and restrained metastasis by modulating MAPK, PI3K/Akt, and Wnt/β-catenin, which are three key signaling pathways (Li et al. 2011). Additionally, salidroside has been shown to enhance immune-mediated tumor clearance and inhibit angiogenesis, further contributing to its anti-cancer efficacy (Gakidou et al. 2008; Vu et al. 2018). These properties, combined with their low toxicity and potential synergistic effects with conventional therapies, highlighted salidroside as a compelling candidate for cancer treatment with a good safety profile (Fan et al. 2020). Furthermore, salidroside has been used previously for the treatment of ovarian and endometrial cancer (Yang et al. 2023; Yu and Feng 2024). However, further research is needed to fully elucidate its therapeutic potential and clinical applicability in cervical cancer. The present study aimed to elucidate the pharmacological mechanisms of salidroside in cervical cancer by integrating network pharmacology, molecular docking, and in vitro validation, to identify potential therapeutic targets and clarify its underlying mode of action. Thus, establishing a research foundation for further research before any clinical application. Materials and methods Acquisition of target genes of salidroside The 2D molecular structure of salidroside was downloaded from the PubChem website (https://pubchem.ncbi.nlm.nih.gov/) (PubChem CID: 159278) (Kim 2016), and target genes were explored in the Swiss Target Prediction database (http://www.swisstargetprediction.ch/) (Daina et al. 2019), and PharmMapper (http://lilab-ecust.cn/pharmmapper/). Investigation of cervical cancer target genes Cervical cancer gene expression datasets were obtained from two publicly available databases: the Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/) and The Cancer Genome Atlas (TCGA, https://portal.gdc.cancer.gov/). For GEO datasets, we searched using the keywords "cervical cancer", "gene expression", "microarray", and "RNA-seq". The relevant dataset (GSE63514) was selected based on sample size, platform type, and availability of clinical information. The raw expression matrices and corresponding platform annotation files were downloaded for subsequent analysis. For TCGA data, we selected the "Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (CESC)" project under the "Transcriptome Profiling" category. Raw data from GEO and TCGA were preprocessed using R (version 4.4.1), including removing genes or samples with excessive missing values, log2 transformation, and normalization. Bioinformatics studies All bioinformatic analyses were performed using R software (version 4.4.1; https://www.r-project.org/). The Limma Package facilitated differential expression analysis, identifying differentially expressed genes (DEGs) based on two criteria: p < 0.05 and an absolute log2 fold change (|log2FC|) of at least 1. Functional annotation of DEGs was done via Gene Ontology (GO) enrichment analysis, KEGG pathway analysis, utilizing the Cluster Profiler package. Survival analysis for the core genes was conducted using the GEPIA (Gene Expression Profiling Interactive Analysis, http://gepia.cancer-pku.cn/) database, with overall survival (OS) as the primary endpoint. Molecular docking studies methodology Ligand preparation The structure of Salidroside was drawn in the widely used chemical structure drawing software, ChemDraw v20.1. The geometry of this structure was optimized by using the field force MMFF94 utility of Chem3D software, and structures were saved in SDF format. The optimized structure of the compound was loaded in Auto Dock tools and saved in PDBQT format for further molecular docking studies(Morris et al. 2009). Protein preparation X-ray crystallographic structure of the Caspase 3 V266A was retrieved from the Protein Data Bank (https://www.rcsb.org) with PDB ID: 5I9B. These X-ray crystallographic structures were inserted into Visualizer (Discovery Studio), and water molecules, unwanted ligands, as well as hydrogen atoms were removed. These proteins were taken in the PDB format for protein preparation and loaded into AutoDock. Kollman charges were added, and the protein structure was saved in PDBQT format. Furthermore, docking studies were continued with AutoDock, and binding interactions of each pose were analyzed in Visualizer (Discovery Studio). In silico pharmacokinetic properties of salidroside SwissADME online server analyzed the physicochemical and pharmacokinetic characteristics (absorption, distribution, metabolism, and excretion) of salidroside. To determine the pharmacokinetic profile, the SMILES format for salidroside was retrieved from Chem-Draw and uploaded to the online server (Lipinski et al. 1997). In vitro experimentation Cell culture, drugs, and reagents The HeLa cell line was used, which was purchased from the American Type Culture Collection (ATCC, Manassas, VA). DMSO (dimethyl sulfoxide) was used to dissolve salidroside (Sigma, USA, purity ≥ 98.0%), which was subsequently diluted in culture medium. The final DMSO concentration in all treatments, including the control group, was maintained at 0.1% (v/v) to avoid solvent-related effects. The Cell Counting Kit (CCK-8) from Beyotime (Shanghai, China) was used. The Annexin V-PE/7-AAD Apoptosis Kit and BCA protein assay kits (Vazyme, Nanjing, China). were used. Anti-MMP1 and Anti-MMP3 antibodies (Proteintech, Wuhan, China) were used. CCK-8 Cell viability was assessed according to the procedure outlined in the manufacturer's instructions (CCK-8 Kit). For cell attachment purposes, HeLa cells were seeded in a 96-well plate (5 × 103 cells/well) and left to incubate overnight. After treatment with the desired compounds or conditions, CCK-8 solution (10 µL) was added to wells, and incubation was done (at 37 °C) for two hours in a controlled condition (5% CO2 and humidified atmosphere). Absorbance was taken at 450 nm using a microplate reader (EnSpire, PerkinElmer, USA). All the experiments were performed in triplicate. For cell viability experiments, salidroside was used in various concentrations (0, 5, 10, 20, 40, 80, 160, and 320 µg/mL). Apoptosis assessment in cells A flow cytometer (FCM) with Annexin V-PE/7-ADD double staining was used for apoptosis assessment. After treatment, the HeLa cells were collected, and washing was done twice with PBS. A cell suspension was prepared in binding buffer (1 × 16⁶ cells/mL). For apoptosis detection, 5 µL of Annexin V-PE and 5 µL of 7-AAD were added to 100 µL of suspended cells, and incubation was done in the dark at room temperature for 15 min. After it, the binding buffer (400 µL) was added to the cells, and the samples were analyzed using an FCM (CytoFlex S, Beckman, USA). For apoptosis experiments, the salidroside concentration used was 80 µg/mL. Protein estimation by western blotting Protein expression was assessed by Western blot analysis. Cellular proteins were extracted using ice-cold RIPA lysis buffer added with protease and phosphatase inhibitor cocktails, followed by incubation on ice for 30 min. Protein concentrations were measured using a BCA protein quantification kit (Thermo Fisher). Equal amounts of protein (20–40 µg per sample) were separated by electrophoresis on 10–12% SDS–polyacrylamide gels and then transferred to PVDF membranes (Millipore) via semi-dry electroblotting. To minimize nonspecific binding, the membranes were blocked with 5% skim milk in TBST (Tris-buffered saline) for 1 h at room temperature. Next, the membranes were incubated with primary antibodies (dilution ratio 1:500) at 4 °C overnight. After three washes with TBST, HRP-conjugated secondary antibodies (dilution ratio 1:2000) were applied for 1 h at room temperature. Following another round of TBST washes, protein bands were visualized using an enhanced chemiluminescence (ECL) detection system (Bio-Rad). Band intensities were quantified using ImageJ software, with GAPDH serving as an internal loading control for normalization (AlAsmari et al. 2021, 2022). Statistical analysis Quantitative data were expressed as mean values with standard deviation (Mean ± SD). Intergroup comparisons were evaluated using one-way ANOVA to determine differences among experimental conditions. Statistical computations were done using GraphPad Prism (version 8.0.1, GraphPad Software Inc.), with a threshold of p < 0.05 set as the criterion for statistical significance. Results Cervical cancer potential target assessment To find out the therapeutic mechanism of salidroside in cervical cancer, we initiated our study by conducting a comprehensive genomic analysis. Cervical cancer-related genes were thoroughly identified through bioinformatic interrogation of publicly available datasets from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. We identified 6,192 differentially expressed genes (DEGs) in the TCGA database (Fig. 1A), with a significance threshold of p < 0.05 and a log2 fold change (log2FC) > 0.5. Additionally, analysis of the GEO dataset (GSE63514) revealed 727 DEGs related to cervical cancer (Fig. 1B). By further analyzing the overlapping genes between the two databases, we identified 279 common genes associated with cervical cancer, which were selected for subsequent analysis (Fig. 1C).Fig. 1(A) DEGs identified from the TCGA database in cervical cancer. (B) DEGs from the GEO dataset. (C) 279 common genes were identified from the overlap between TCGA and GEO datasets (A) DEGs identified from the TCGA database in cervical cancer. (B) DEGs from the GEO dataset. (C) 279 common genes were identified from the overlap between TCGA and GEO datasets Potential targets of salidroside The potential target proteins of salidroside were predicted using the Swiss Target Prediction (http://www.swissadme.ch). This site enables you to assess the likely macromolecular targets of a small molecule, which is presumed to be bioactive. The prediction is based on a blend of 2D and 3D similarity with a database of 37,000 known active compounds across over 3,000 proteins from three distinct species, including Homo sapiens, Mus musculus, and Rattus norvegicus. In the current study, we selected targets of human origin and found that Salidroside has a 66.7% potential to inhibit the lyases, as presented in a pie chart in Fig. 2. Moreover, Salidroside exhibited a potential of 13.3% to inhibit hydrolases. For molecular docking studies, Caspase 3 (EC 3.4.22.) protein was selected as a possible target for anticancer activity, as this specific protein belongs to the hydrolases class of enzymes. A detailed list of target proteins has been attached in the supplementary data.Fig. 2A pie chart for identification of potential salidroside targets using Swiss Target Prediction A pie chart for identification of potential salidroside targets using Swiss Target Prediction Potential targets of salidroside in cervical cancer We identified 10 genes as a potential target of salidroside (Fig. 3A). The KEGG (Kyoto Encyclopedia of Gene and Genomes) pathway analysis revealed that salidroside might exert its anti-cervical cancer effects through the modulation of multiple signaling pathways, especially the IL-17, TNF-α, and Relaxin signaling pathways (Fig. 3B). The IL-17 signaling pathway promotes tumor progression through inflammatory cytokine release, angiogenesis, and immune cell recruitment within the tumor microenvironment. Salidroside might downregulate IL-17-associated targets, suggesting that the compound may attenuate chronic inflammation and tumor-promoting immune responses. Similarly, the TNF-α pathway, which is associated with cell survival and inflammatory signaling via NF-κB activation, was significantly affected, indicating that salidroside may suppress TNF-α–mediated proliferation and enhance apoptosis in cervical cancer cells (Ozkan and Bakar-Ates 2020). Furthermore, modulation of the Relaxin signaling pathway, a pathway implicated in extracellular matrix (ECM) remodeling and metastasis, suggests that salidroside could limit tumor cell invasion and migration by stabilizing ECM integrity.Fig. 3(A) We identified 10 overlapping potential targets of salidroside for cervical cancer. (B) KEGG pathway analysis showed that salidroside affects IL-17, TNF, and Relaxin signaling pathways (C). GO enrichment analysis indicated that salidroside modulates extracellular structure and matrix organization (A) We identified 10 overlapping potential targets of salidroside for cervical cancer. (B) KEGG pathway analysis showed that salidroside affects IL-17, TNF, and Relaxin signaling pathways (C). GO enrichment analysis indicated that salidroside modulates extracellular structure and matrix organization GO enrichment analysis demonstrated that salidroside predominantly influences biological processes related to extracellular structure organization and extracellular matrix organization (Fig. 3C). These processes have a close relation with cellular adhesion, migration, and metastasis, frequently dysregulated in cervical carcinogenesis. The downregulation of matrix metalloproteinases (MMP1 and MMP3), identified as key hub genes, further supports the hypothesis that salidroside inhibits tumor progression by impairing ECM degradation and suppressing metastatic signaling (Feng et al. 2014). Collectively, these results suggest that salidroside mitigates cervical cancer development by targeting inflammation-related (IL-17, TNF-α) and ECM-related (Relaxin) pathways, thereby disrupting the tumor-promoting microenvironment and restraining metastatic behavior. Salidroside targets key molecular pathways To explore the key molecular targets of salidroside in cervical cancer, we conducted survival analysis on the ten candidate targets obtained from prior intersectional screening. The Kaplan–Meier survival curves demonstrated that the elevated expression of MMP1 and MMP3 correlated with significantly poor clinical outcomes in cervical cancer patients. Furthermore, comparative gene expression analysis revealed that MMP1 and MMP3 were substantially upregulated in cervical tumor tissues relative to normal controls. These findings suggested that MMP1 and MMP3 may represent critical therapeutic targets through which salidroside exerts its anti-tumor effects (Fig. 4A-B).Fig. 4(A-B) Survival analysis of 10 cross-targets between salidroside and cervical cancer. Molecular docking of salidroside complexed with (C) Putative binding mode of Salidroside inside the active pocket of Caspase 3 V266A (PDB ID: 5i9b) (A-B) Survival analysis of 10 cross-targets between salidroside and cervical cancer. Molecular docking of salidroside complexed with (C) Putative binding mode of Salidroside inside the active pocket of Caspase 3 V266A (PDB ID: 5i9b) Molecular docking analysis In molecular docking studies, the protein crystal structure of the HeLa cell line enzymatic protein Caspase 3 V266A (PDB ID: 5i9b) was used (Maciag et al. 2016). This crystallized protein does not contain any co-crystallized ligand; therefore, for docking purposes, the previously reported active site was selected, which contains Arg 207, Ser 205, Ser 65, and Ser 209 as key amino acid residues. The ligand docking scores indicate the binding affinity between the ligand and the receptor. The ligand that presents the highest negative value is deemed to possess the best docked pose. The salidroside was docked in a previously reported active site (Al-Jumaili et al. 2023). It has been demonstrated that the ligand exhibited strong binding affinity for the Caspase 3 enzymatic protein, achieving a docking score of −6.4562 KCal/mole. The amino acid residues Arg 207, Ser 205, Ser 65, and Ser 209 play a crucial role as the active site in the docking studies of the target Capsase 3 protein (Al-Jumaili et al. 2023). Salidroside exhibited six hydrogen bonds with Arg64, Glu123, Gln161, Ser205, and Arg207 amino acid residues inside the active site of the target protein. These amino acids developed hydrogen bonds with the hydroxyl groups of the ligand molecule. Moreover, there was a C-H bond with Ser120 and a π-alkyl interaction with Cys163 as presented in Fig. 4C. In Silico ADME analysis SwissADME is an online tool that is freely available for analyzing pharmacokinetics, including absorption, distribution, metabolism, and excretion (ADME). Salidroside follows the drug-ability criteria as no violation had been found for Lipinski’s rule of five and PAINS criteria. Salidroside was found to be highly absorbed from the GIT, but was unable to cross the blood–brain barrier, and this point is advantageous in terms of toxicity and safety of salidroside. in vitro validation Salidroside inhibited cervical cancer cell proliferation Quantitative analysis confirmed salidroside’s concentration-dependent cytotoxic effects on HeLa cells (IC50 = 270.5 μg/mL) as measured by CCK-8 assay (Fig. 5A). Additionally, the plate clone formation assay revealed a reduction in HeLa cell clone formation following salidroside treatment compared to the corresponding normal control groups (non-treated) (Fig. 5B), implying that salidroside exerts a cytostatic impact on HeLa cells (a cancerous cell line).Fig. 5(A) HeLa cells were exposed to culture medium containing various concentrations of salidroside, and then cell viability was measured using the CCK-8 assay (n = 3). (B) A colony-forming growth assay was used to detect cell colony formation ability, and the colonies were counted and captured (n = 3). (C) Representative picture of apoptosis assayed using FCM, and percentage of apoptotic cells (n = 3). (D) MMP1 and MMP3 expression levels in HeLa cells by WB (n = 3). *P < 0.05, **P < 0.01.For cell viability, we used 6-well plate of approximately 35 mm and a surface area of 9.5–9.6 cm2, average cell count was 1.5 × 106 (A) HeLa cells were exposed to culture medium containing various concentrations of salidroside, and then cell viability was measured using the CCK-8 assay (n = 3). (B) A colony-forming growth assay was used to detect cell colony formation ability, and the colonies were counted and captured (n = 3). (C) Representative picture of apoptosis assayed using FCM, and percentage of apoptotic cells (n = 3). (D) MMP1 and MMP3 expression levels in HeLa cells by WB (n = 3). *P < 0.05, **P < 0.01.For cell viability, we used 6-well plate of approximately 35 mm and a surface area of 9.5–9.6 cm2, average cell count was 1.5 × 106 Salidroside-induced apoptosis In the salidroside group, the quantity of both early and late apoptotic cervical cancer cells increased when compared to control cells (Fig. 5C), which is indicative that salidroside might promote apoptosis in cervical cancer cells. Salidroside downregulated the protein levels in cells Based on survival analysis results, the protein expression level of the core targets, such as MMP1 and MMP3, was assessed. Western blotting revealed that after 24 h of treatment with various concentrations of salidroside extract, the MMP1 and MMP3 proteins displayed the anticipated alterations. When compared to the control group, there was a significant reduction of MMP1 and MMP3 protein expression in the salidroside-administered group (Fig. 5D). The pharmacological mechanism is elaborated in Fig. 6.Fig. 6Pharmacological mechanism of salidroside in the treatment of cervical cancer. Genes associated with cervical cancer were gathered from The Cancer Genome Atlas Program (TCGA), Gene Expression Omnibus (GEO) databases, and network pharmacology. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) find out MMP1 and MMP3 as potential genes. Salidroside mitigates cervical cancer by targeting inflammation-related (IL-17, TNF-α) and ECM-related (Relaxin) pathways.It also inhibit Hela cell viability, induced apoptosis and degrarede MMp and MMp3 Pharmacological mechanism of salidroside in the treatment of cervical cancer. Genes associated with cervical cancer were gathered from The Cancer Genome Atlas Program (TCGA), Gene Expression Omnibus (GEO) databases, and network pharmacology. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) find out MMP1 and MMP3 as potential genes. Salidroside mitigates cervical cancer by targeting inflammation-related (IL-17, TNF-α) and ECM-related (Relaxin) pathways.It also inhibit Hela cell viability, induced apoptosis and degrarede MMp and MMp3 Discussion Globally, cervical carcinoma is one of the most prevalent malignancies affecting the female reproductive system. Despite therapeutic advances, disease recurrence continues to present significant clinical challenges and health risks for patients in the world (Arbyn et al. 2020). Despite the availability of various treatment options for cervical cancer, an ideal pharmacological treatment regimen is still lacking. Screening effective components from traditional Chinese medicine for cervical cancer treatment has become an important method for developing new drugs. In recent years, salidroside and its targeted multi-pathway monomeric compounds have been widely studied as potential anti-tumor agents (Wang et al. 2021). Salidroside is a bioactive compound that exhibits tripartite pharmacological actions, including the reduction of oxidative stress, suppression of inflammatory responses, and inhibition of malignant cell growth, supporting its investigational use in oncology. However, the specific mechanisms of salidroside's action in cervical carcinoma are not well established, and further investigation may help explore its pharmacological effects and clinical application potential. An integrated analysis of the drug targets of salidroside and the disease targets of cervical cancer was conducted. KEGG and GO enrichment results indicated that MMP1 and MMP3 might be potential targets of salidroside in treating cervical cancer. The PI3K/Akt is a vital signaling pathway in various stages of cell growth and survival. Its role is well established in the onset and progression of numerous diseases (Kessenbrock et al. 2010; Gialeli et al. 2011). MMP1 and MMP3 are considered crucial targets of the PI3K/Akt signaling pathway. They activate this by degradation of the ECM and release IGF1 (insulin-like growth factor 1), which in turn supports tumor cell survival and proliferation (Hu et al. 2010). Survival analysis results indicated that MMP1 and MMP3 are the core therapeutic targets of salidroside in treating cervical cancer. Molecular docking studies demonstrated that salidroside has a strong binding affinity with MMP1 and MMP3 and can significantly reduce their expression in cervical carcinoma cells. Thus, our study findings suggested that salidroside inhibited MMP1 and MMP3 protein expression, further supporting the hypothesis that these might induce apoptosis and halt the cancerous cells' proliferation and growth. In vitro cell line experiments have established that salidroside inhibited the growth of cervical cancer cells. Previous research has shown that salidroside inhibited the activity of Cyclin D1 and CDK4/6, inducing G1 phase cell cycle arrest, thereby suppressing the tumor cell proliferation. Our study findings are also consistent with this study (Hu et al. 2010). Apoptotic cell death, happening through either the mitochondrial (Type II) or death receptor (Type I) pathways, constitutes a pivotal regulatory mechanism in disease etiology and advancement (Ma et al. 2015). Previous studies established that salidroside triggers both apoptotic cell death and autophagic flux through modulation of the phosphoinositide-3-kinase/AKT/mTOR signaling axis (Rong et al. 2020). In this study, in vitro experiments revealed that salidroside-dependent apoptosis in cervical carcinoma was purely dependent on its dose. Our study findings are consistent with already published research on phytochemicals such as curcumin, which also inhibit cervical cancer progression by inhibiting NFκB activation by preventing IκBα phosphorylation. Curcumin also inhibits cancer cell growth and progression by inhibiting and Wnt/β-catenin signaling pathway (Divya and Pillai 2006; Ghasemi et al. 2019). The results of in vitro studies are in line with the predictions made using the network pharmacology approach. Salidroside exerted potent anti-neoplastic effects in cervical cancer models. In vitro studies revealed three key mechanisms: significant suppression of cellular proliferation, activation of programmed cell death, and marked downregulation of matrix metalloproteinase activity via MMP1/MMP3 downregulation. Therefore, salidroside might be an ideal therapeutic agent for cervical cancer, although its underlying molecular mechanisms require further investigation. A few other chemicals, like curcumin, downregulate MMP1 and MMP2 and thus inhibit cervical cancer cell invasion and migration (Zheng et al. 2024). Similarly, resveratrol inhibits cervical cancer cell invasion and migration through NF-κB-mediated MMP9 downregulation. It also inhibits angiogenesis by interfering with PI3K/Akt and ERK1/2 pathways (He et al. 2021). This study has a few limitations, such as the use of publicly available datasets, which may contain sampling and processing bias, and the predictive nature of network pharmacology, which depends on database completeness. Molecular docking results do not fully reflect dynamic in vivo conditions, and the in vitro validation was restricted to a single cell line without in vivo confirmation of efficacy or safety. Future work might include multiple cervical cancer cell lines, in vivo animal models, and patient-derived samples to better capture clinical relevance. Molecular dynamics simulations may refine target–ligand interaction insights, while combinatorial therapy studies might reveal synergistic effects. Further mechanistic studies on MMP1- and MMP3-related molecular pathways could uncover additional therapeutic targets. Our study has a few limitations, such as we have used a single cell line, and we have limited in vivo data. Conclusion By combining the TCGA and GEO databases, we analyzed the disease targets of cervical cancer. Using network pharmacology, we screened for the potential targets of salidroside. Bioinformatic pathway interrogation (KEGG/GO) identified MMP1 and MMP3 as probable molecular moderators of salidroside’s anti-cervical cancer activity. Survival analysis identified MMP1 and MMP3 as the core therapeutic targets of salidroside for cervical cancer. Molecular docking confirmed the binding potential of salidroside with MMP1 and MMP3. Moreover, the in vitro experiments validated the involvement of the predicted target proteins (MMP1 and MMP3) in mediating salidroside’s effects on cervical cancer cell growth and apoptosis. These findings corroborated the reliability of our network pharmacology analysis, showing strong consistency between computational predictions and biological evidence. Although the present results emphasized the promising anti-tumor potential of salidroside in cervical cancer through the identified molecular mechanisms, further comprehensive investigations are needed to fully elucidate its therapeutic applicability. Supplementary information Below is the link to the electronic supplementary material. Supplementary file1 (PDF 32.4 KB) Supplementary file1 (PDF 32.4 KB)